Clinical Trial News and Research RSS Feed - Clinical Trial News and Research

Study: Cervical pessary does not reduce preterm births, neonatal complications in twin pregnancies

Study: Cervical pessary does not reduce preterm births, neonatal complications in twin pregnancies

Having twins accounts for only 1.5% of all births but 25% of preterm births, the leading cause of infant mortality worldwide. Successful strategies for reducing singleton preterm births include prophylactic use of progesterone and cervical cerclage in patients with a prior history of preterm birth. [More]
New European project creates different tools to manage healthcare through technology

New European project creates different tools to manage healthcare through technology

The future is here: everyday healthcare is now intertwined with technology at every level. From improved record-keeping to smartphone apps that patients can use to track health progress, the technological infrastructure that has grown up around healthcare provides benefits that the previous generation couldn't dream of. [More]
Researchers provide new insights into biology of aging, age-related diseases

Researchers provide new insights into biology of aging, age-related diseases

The scientific team of a new biotech company Gero in collaboration with one of the leading academics in the field of aging Prof. Robert J. Shmookler Reis (current world record holder in life extension for model animals - 10 fold for nematodes) has recently brought new insights into biology of aging and age-related diseases, primarily, around the stability and stress resistance of certain gene regulatory networks. [More]
Can-Fite BioPharma announces Q2 financial results for 2015, updates drug development programs

Can-Fite BioPharma announces Q2 financial results for 2015, updates drug development programs

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs being developed to treat inflammatory diseases, cancer and sexual dysfunction, today reported financial results for the six months ended June 30, 2015 and updates on its drug development programs. [More]
Soligenix obtains additional funding from NIAID to advance development of OrbeShield for GI ARS treatment

Soligenix obtains additional funding from NIAID to advance development of OrbeShield for GI ARS treatment

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that the National Institute of Allergy and Infectious Diseases has exercised its option to advance preclinical development of OrbeShield (oral beclomethasone 17,21-dipropionate or oral BDP). [More]
Computational fluid dynamics modeling confirms better blood flow with new stent graft design

Computational fluid dynamics modeling confirms better blood flow with new stent graft design

Vascular surgeon Pat Kelly of Sanford Health in Sioux Falls, South Dakota, knew his patients were doing better with the stent graft he designed, but he wanted a better understanding of the mechanics before testing the device more widely in a clinical trial. For that, he reached out to South Dakota State University. [More]
Researchers design online database to help researchers identify cancer gene mutations

Researchers design online database to help researchers identify cancer gene mutations

Many clinical trials use genome sequencing to learn which gene mutations are present in a patient's tumor cells. The question is important because targeting the right mutations with the right drugs can stop cancer in its tracks. But it can be difficult to determine whether there is evidence in the medical literature that particular mutations might drive cancer growth and could be targeted by therapy, and which mutations are of no consequence. [More]
Cryoport to support future clinical trials for Opexa's personalized T-cell immunotherapy programs for MS, NMO

Cryoport to support future clinical trials for Opexa's personalized T-cell immunotherapy programs for MS, NMO

Cryoport, Inc., the leading provider of advanced cryogenic logistics solutions for the life sciences industry, today announced that its validated cryogenic logistics solution will support future clinical trials for Opexa Therapeutics' lead personalized T-cell immunotherapy programs for Multiple Sclerosis ("MS") and Neuromyelitis Optica ("NMO"). [More]
Breakthrough antibody therapy shows significant promise against drug-resistant multiple myeloma

Breakthrough antibody therapy shows significant promise against drug-resistant multiple myeloma

In its first clinical trial, a breakthrough antibody therapy produced at least partial remissions in a third of patients with multiple myeloma who had exhausted multiple prior treatments, investigators at Dana-Farber Cancer Institute and other organizations report today online in the New England Journal of Medicine. [More]
ASTRO awards $675,000 to seven physician-researchers to advance radiation oncology research

ASTRO awards $675,000 to seven physician-researchers to advance radiation oncology research

The American Society for Radiation Oncology has selected seven leading physician-researchers to receive a total of $675,000 in awards and grants to advance radiation oncology research. Together, the seven funding grants, including ASTRO Junior Faculty Career Research Training Award, the ASTRO Residents/Fellows in Radiation Oncology Research Seed Award and the ASTRO/Radiation Oncology Institute Comparative Effectiveness Research Award, will support studies in radiation and cancer biology, radiation physics, translational research, outcomes/health services research and comparative effectiveness research within radiation oncology. [More]
Novartis receives FDA approval for expanded use of Promacta for younger children with rare blood disorder

Novartis receives FDA approval for expanded use of Promacta for younger children with rare blood disorder

Novartis announced today that the US Food and Drug Administration has approved an expanded use for Promacta to include children 1 year of age and older with chronic immune thrombocytopenia who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy. [More]
New studies evaluate viral suppression rate of HIV-infected pregnant women at delivery

New studies evaluate viral suppression rate of HIV-infected pregnant women at delivery

Pregnancy could be a turning point for HIV-infected women, when they have the opportunity to manage their infection, prevent transmission to their new baby and enter a long-term pattern of maintenance of HIV care after giving birth--but most HIV-infected women aren't getting that chance. [More]
Epinephrine delay decreases survival for children with in-hospital, nonshockable cardiac arrest

Epinephrine delay decreases survival for children with in-hospital, nonshockable cardiac arrest

Among children with in-hospital cardiac arrest with an initial nonshockable heart rhythm who received epinephrine (adrenaline), delay in administration of epinephrine was associated with a decreased chance of 24-hour survival and survival to hospital discharge, according to a study in the August 25 issue of JAMA. [More]
Omega-3 supplements fail to slow cognitive decline in older persons, NIH clinical study shows

Omega-3 supplements fail to slow cognitive decline in older persons, NIH clinical study shows

While some research suggests that a diet high in omega-3 fatty acids can protect brain health, a large clinical trial by researchers at the National Institutes of Health found that omega-3 supplements did not slow cognitive decline in older persons. With 4,000 patients followed over a five-year period, the study is one of the largest and longest of its kind. [More]
AirXpanders' pivotal XPAND trial meets primary endpoint in patients who have undergone mastectomy

AirXpanders' pivotal XPAND trial meets primary endpoint in patients who have undergone mastectomy

AirXpanders Inc., a medical device company focused on the design, manufacture, sale and distribution of the AeroForm Tissue Expander, is pleased to report that its pivotal XPAND trial has met its primary endpoint in patients who have undergone a mastectomy. [More]
FDA, EMA accept filing applications for Boehringer Ingelheim's afatinib to treat patients with advanced SCC of the lung

FDA, EMA accept filing applications for Boehringer Ingelheim's afatinib to treat patients with advanced SCC of the lung

Boehringer Ingelheim today announced that both the U.S. Food and Drug Administration and the European Medicines Agency have accepted filing applications for afatinib for the treatment of patients with advanced squamous cell carcinoma (SCC) of the lung progressing after treatment with first-line chemotherapy. [More]
Clementia expands enrollment to include children with FOP in ongoing Phase 2 clinical trial

Clementia expands enrollment to include children with FOP in ongoing Phase 2 clinical trial

Clementia Pharmaceuticals, Inc. today announced the initiation of enrollment of children as young as 6 years old in the company's ongoing Phase 2 study of palovarotene for the treatment of fibrodysplasia ossificans progressiva (FOP). [More]
Tocagen's Toca 511 & Toca FC receives FDA orphan drug designation for treatment of glioblastoma

Tocagen's Toca 511 & Toca FC receives FDA orphan drug designation for treatment of glioblastoma

Tocagen Inc., a clinical-stage immuno-oncology company, today announced that the U.S. Food and Drug Administration has granted orphan drug designation to the company's lead immuno-oncology product candidate, Toca 511 & Toca FC, for the treatment of glioblastoma. [More]
Study shows significant link between macular pigment levels in the eye and cognitive function

Study shows significant link between macular pigment levels in the eye and cognitive function

Ongoing European Research Council-funded research at Waterford Institute of Technology's Macular Pigment Research Group is investigating the potential link between cognitive function and levels of a vital eye pigment linked to diet. The study suggests that measuring macular pigment offers potential as a biomarker of cognitive health [More]
Dr. Sharma receives research award from ASCO to continue study on triple-negative breast cancer

Dr. Sharma receives research award from ASCO to continue study on triple-negative breast cancer

Dr. Sharma was awarded the 2015 Advanced Clinical Research Award in Breast Cancer from the American Society of Clinical Oncology to continue her research on triple-negative breast cancer. [More]
Advertisement
Advertisement